MX2022000243A - Nuevos compuestos heterociclicos. - Google Patents
Nuevos compuestos heterociclicos.Info
- Publication number
- MX2022000243A MX2022000243A MX2022000243A MX2022000243A MX2022000243A MX 2022000243 A MX2022000243 A MX 2022000243A MX 2022000243 A MX2022000243 A MX 2022000243A MX 2022000243 A MX2022000243 A MX 2022000243A MX 2022000243 A MX2022000243 A MX 2022000243A
- Authority
- MX
- Mexico
- Prior art keywords
- heterocyclic compounds
- new heterocyclic
- compounds
- new
- processes
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Abstract
La invención proporciona nuevos compuestos heterocíclicos que tienen la fórmula general (I) en donde R1, R2, X y Y son como se definen en la presente, composiciones que incluyen los compuestos, procesos para manufacturar los compuestos y métodos para usar los compuestos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19185088 | 2019-07-09 | ||
PCT/EP2020/069074 WO2021005034A1 (en) | 2019-07-09 | 2020-07-07 | New heterocyclic compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022000243A true MX2022000243A (es) | 2022-02-03 |
Family
ID=67220669
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022000243A MX2022000243A (es) | 2019-07-09 | 2020-07-07 | Nuevos compuestos heterociclicos. |
Country Status (18)
Country | Link |
---|---|
US (1) | US20220242876A1 (es) |
EP (1) | EP3997096A1 (es) |
JP (1) | JP2022539604A (es) |
KR (1) | KR20220034104A (es) |
CN (1) | CN114096545A (es) |
AR (1) | AR119376A1 (es) |
AU (1) | AU2020311584A1 (es) |
BR (1) | BR112021026899A2 (es) |
CA (1) | CA3145338A1 (es) |
CL (1) | CL2022000019A1 (es) |
CO (1) | CO2022000186A2 (es) |
CR (1) | CR20220004A (es) |
IL (1) | IL288987A (es) |
MX (1) | MX2022000243A (es) |
PE (1) | PE20220515A1 (es) |
TW (1) | TW202116781A (es) |
WO (1) | WO2021005034A1 (es) |
ZA (1) | ZA202110352B (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019134985A1 (en) | 2018-01-08 | 2019-07-11 | F. Hoffmann-La Roche Ag | Octahydropyrido[1,2-alpha]pyrazines as magl inhibitors |
EP3837263A1 (en) | 2018-08-13 | 2021-06-23 | F. Hoffmann-La Roche AG | New heterocyclic compounds as monoacylglycerol lipase inhibitors |
EP4028403B1 (en) | 2019-09-12 | 2023-11-22 | F. Hoffmann-La Roche AG | 4,4a,5,7,8,8a-hexapyrido[4,3-b][1,4]oxazin-3-one compounds as magl inhibitors |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2014110401A (ru) * | 2011-08-19 | 2015-09-27 | Мерк Шарп И Доум Корп. | Ингибиторы внешнего медуллярного калиевого канала почек |
EP2934533B1 (en) * | 2012-12-19 | 2017-11-15 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
US10323038B2 (en) * | 2015-11-20 | 2019-06-18 | Abide Therapeutics, Inc. | Pyrazole compounds and methods of making and using same |
BR112019014099A2 (pt) * | 2017-01-23 | 2020-02-11 | Pfizer Inc. | Compostos espiro-heterocíclico como inibidores de magl |
JOP20190267A1 (ar) * | 2017-05-23 | 2019-11-18 | Lundbeck La Jolla Research Center Inc | مثبطات بيرازول magl |
-
2020
- 2020-07-07 CA CA3145338A patent/CA3145338A1/en active Pending
- 2020-07-07 BR BR112021026899A patent/BR112021026899A2/pt unknown
- 2020-07-07 JP JP2022500908A patent/JP2022539604A/ja active Pending
- 2020-07-07 CN CN202080050165.3A patent/CN114096545A/zh active Pending
- 2020-07-07 AU AU2020311584A patent/AU2020311584A1/en active Pending
- 2020-07-07 KR KR1020227000611A patent/KR20220034104A/ko active Search and Examination
- 2020-07-07 MX MX2022000243A patent/MX2022000243A/es unknown
- 2020-07-07 EP EP20740259.5A patent/EP3997096A1/en active Pending
- 2020-07-07 CR CR20220004A patent/CR20220004A/es unknown
- 2020-07-07 PE PE2021002265A patent/PE20220515A1/es unknown
- 2020-07-07 WO PCT/EP2020/069074 patent/WO2021005034A1/en unknown
- 2020-07-08 AR ARP200101928A patent/AR119376A1/es unknown
- 2020-07-08 TW TW109123050A patent/TW202116781A/zh unknown
-
2021
- 2021-12-13 ZA ZA2021/10352A patent/ZA202110352B/en unknown
- 2021-12-14 IL IL288987A patent/IL288987A/en unknown
-
2022
- 2022-01-04 CL CL2022000019A patent/CL2022000019A1/es unknown
- 2022-01-06 US US17/569,749 patent/US20220242876A1/en active Pending
- 2022-01-13 CO CONC2022/0000186A patent/CO2022000186A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
CR20220004A (es) | 2022-01-31 |
BR112021026899A2 (pt) | 2022-05-10 |
CN114096545A (zh) | 2022-02-25 |
JP2022539604A (ja) | 2022-09-12 |
AU2020311584A1 (en) | 2022-01-20 |
EP3997096A1 (en) | 2022-05-18 |
KR20220034104A (ko) | 2022-03-17 |
PE20220515A1 (es) | 2022-04-07 |
IL288987A (en) | 2022-02-01 |
TW202116781A (zh) | 2021-05-01 |
AR119376A1 (es) | 2021-12-15 |
CO2022000186A2 (es) | 2022-01-17 |
US20220242876A1 (en) | 2022-08-04 |
WO2021005034A1 (en) | 2021-01-14 |
ZA202110352B (en) | 2022-08-31 |
CL2022000019A1 (es) | 2022-10-21 |
CA3145338A1 (en) | 2021-01-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12021551167A1 (en) | New heterocyclic compounds | |
PH12021500013A1 (en) | New heterocyclic compounds as monoacylgylcerol lipase inhibitors | |
PH12021500015A1 (en) | New heterocyclic compounds as monoacylglycerol lipase inhibitors | |
MX2021014441A (es) | Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos. | |
PH12017502090A1 (en) | Heterocyclic amides as kinase inhibitors | |
MX2020008894A (es) | Inhibidores de oxazin monoacilglicerol lipasa (magl). | |
MX2020004504A (es) | Derivados de fenoximetilo. | |
PH12018500408A1 (en) | Bicyclic compounds as atx inhibitors | |
MX2018001430A (es) | Nuevos compuestos biciclicos como inhibidores duales de autotaxina (atx)/anhidrasa carbonica (ca). | |
MX2018001890A (es) | Compuestos biciclicos como inhibidores de autotaxina (atx). | |
PH12019500664A1 (en) | New isoxazolyl ether derivatives as gaba a alpha5 pam | |
CR20220117A (es) | Compuestos heterocíclicos | |
MX2022003023A (es) | Compuestos heterociclicos. | |
MX2020009234A (es) | Compuestos de heteroarilo como inhibidores de cinasas asociadas con receptores de interleucina-1 (irak) tipo ii y usos de los mismos. | |
MX2022000243A (es) | Nuevos compuestos heterociclicos. | |
MX2022002711A (es) | Nuevos inhibidores heterociclicos de monoacilglicerol lipasa (magl). | |
MY169267A (en) | New aryl-quinoline derivatives | |
MX2020013630A (es) | Analogos de rapamicina y usos de los mismos. | |
CR20230496A (es) | Compuestos heterocíclicos | |
WO2018035346A8 (en) | KINASE INHIBITING COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING CANCER | |
MX2023002224A (es) | Compuestos heterociclicos. | |
MX2021001904A (es) | Formas solidas de benzoxaborol sustituido y composiciones de las mismas. | |
WO2018166993A3 (en) | PYRAZOLOCHLOROPHENYL COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | |
MY188420A (en) | Crystalline forms of (s)-afoxolaner | |
PH12021550320A1 (en) | Bicyclic heteroaryl derivatives |